Assembly Biosciences, Inc. (ASMB) shareholders
Close on Nov 17, 2026Market cap $458.11MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 4,977,089 | 25.10% | 13D (active) amendment | May 22, 2026 |
| Commodore Capital LP Joint filing with Commodore Capital Master LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more | 1,615,981 | 9.90% | 13G (passive) | Aug 8, 2025 |
| Saito Edric C. Joint filing with Farallon Capital Management, L.L.C. (8.10%), Dapice Joshua J. (8.10%) and 13 more | 1,604,590 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| Senai Asefaw, M.D. Joint filing with Paradigm BioCapital Advisors LP (7.80%), Paradigm BioCapital Advisors GP LLC (7.80%) and 1 more | 1,553,748 | 7.80% | 13G (passive) amendment | Jun 30, 2026 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.50%), Rajeev Shah (9.50%) and 1 more | 1,530,615 | 9.50% | 13G (passive) | Aug 11, 2025 |
| JANUS HENDERSON GROUP Ltd. | 1,359,514 | 6.90% | 13G (passive) amendment | Jun 30, 2026 |
| Janus Henderson Group PLC | 1,341,508 | 8.20% | 13G (passive) | Nov 28, 2025 |
| Dapice Joshua J. Joint filing with Wehrly, Mark C. (7.80%), Dreyfuss, Philip D. (7.80%) and 13 more | 1,227,590 | 7.80% | 13G (passive) amendment | Dec 31, 2025 |
| Luo Patrick (Cheng) Joint filing with Wehrly, Mark C. (7.30%), Dapice Joshua J. (7.30%) and 15 more | 1,140,510 | 7.30% | 13G (passive) | Aug 8, 2025 |
| Paradigm BioCapital Advisors GP LLC Joint filing with Paradigm BioCapital Advisors LP (5.40%), Senai Asefaw, M.D. (5.40%) | 865,251 | 5.40% | 13G (passive) | May 4, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ASMB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 4,977,089 | 24.44% | $136.77M | +471,698 | 8.30% |
| Farallon Capital Management LLC | 1,604,590 | 7.88% | $44.09M | +377,000 | 0.20% |
| Paradigm Biocapital Advisors LP | 1,553,748 | 7.63% | $42.70M | +888,497 | 0.80% |
| Commodore Capital LP | 1,415,000 | 6.95% | $38.88M | +415,000 | 2.32% |
| Ra Capital Management, L.P. | 1,020,410 | 5.01% | $28.04M | – | 0.24% |
| Jupiter Topco LLC | 849,309 | 4.17% | $23.37M | New | 0.01% |
| BlackRock, Inc. | 766,819 | 3.77% | $21.07M | +564,076 | 0.00% |
| Parkman Healthcare Partners LLC | 721,181 | 3.54% | $19.82M | +309,954 | 2.03% |
| Vanguard Capital Management LLC | 558,942 | 2.75% | $15.36M | +68,495 | 0.00% |
| Point72 Asset Management, L.P. | 460,593 | 2.26% | $12.66M | +116,488 | 0.01% |
| Seven Fleet Capital Management LP | 433,147 | 2.13% | $11.90M | +377,000 | 1.96% |
| Millennium Management LLC | 298,807 | 1.47% | $8.21M | +65,157 | 0.00% |
| Geode Capital Management, LLC | 280,424 | 1.38% | $7.71M | +147,453 | 0.00% |
| Schonfeld Strategic Advisors LLC | 242,153 | 1.19% | $6.65M | +121,653 | 0.02% |
| Ameriprise Financial Inc | 230,000 | 1.13% | $6.32M | New | 0.00% |
| Dv Equities, LLC | 226,415 | 1.11% | $6.22M | New | 0.89% |
| abrdn plc | 207,047 | 1.02% | $5.69M | New | 0.01% |
| Affinity Asset Advisors, LLC | 190,000 | 0.93% | $5.22M | New | 0.24% |
| B Group, Inc. | 175,706 | 0.86% | $4.83M | – | 2.27% |
| State Street Corp | 171,931 | 0.84% | $4.72M | +115,242 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 93 | 19M | 92.1% | 34 / 35 | 17 / 15 | 7M | 1M |
| Q1 2026 | 75 | 14M | 67.6% | 17 / 28 | 17 / 10 | 2M | 1M |
| Q4 2025 | 69 | 14M | 67.4% | 22 / 23 | 13 / 8 | 2M | 1M |
| Q3 2025 | 57 | 12M | 61.3% | 31 / 16 | 3 / 7 | 9M | 0M |
| Q2 2025 | 33 | 3M | 15.5% | 5 / 7 | 8 / 9 | 0M | 0M |
| Q1 2025 | 37 | 3M | 15.6% | 6 / 11 | 10 / 4 | 0M | 0M |
| Q4 2024 | 35 | 3M | 15.6% | 10 / 11 | 7 / 5 | 2M | 0M |
| Q3 2024 | 30 | 1M | 5.1% | 5 / 8 | 7 / 1 | 0M | 0M |
| Q2 2024 | 27 | 1M | 5.8% | 5 / 9 | 6 / 2 | 1M | 0M |
| Q1 2024 | 24 | 1M | 3.2% | 0 / 10 | 9 / 21 | 0M | 0M |
| Q4 2023 | 45 | 1M | 3.6% | 17 / 9 | 7 / 4 | 0M | 0M |
| Q3 2023 | 32 | 1M | 4.0% | 2 / 3 | 12 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
63 funds held ASMB in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ASMB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 413,284 | 2.03% | $11.36M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 244,994 | 1.20% | $6.73M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 133,292 | 0.65% | $3.66M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 107,386 | 0.53% | $2.70M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 89,271 | 0.44% | $2.45M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 58,396 | 0.29% | $1.62M | 0.00% | May 31, 2026 |
| Franklin Biotechnology Discovery Fund | 40,982 | 0.20% | $1.03M | 0.09% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 33,135 | 0.16% | $910.55K | 0.06% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 23,781 | 0.12% | $597.14K | 0.01% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 21,252 | 0.10% | $587.83K | 0.00% | May 31, 2026 |
| Small Cap Value Fund | 20,728 | 0.10% | $569.61K | 0.08% | Jun 30, 2026 |
| Master Small Cap Index Series | 18,425 | 0.09% | $506.32K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 16,917 | 0.08% | $467.92K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Value Index Fund | 13,750 | 0.07% | $377.85K | 0.02% | Jun 30, 2026 |
| Virtus Biotech Clinical Trials Etf | 13,537 | 0.07% | $339.91K | 0.73% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jason A. Okazaki | CEO and President, Director | 195,532 | 0.96% | Nov 3, 2026 |
| Jeanette M. Bjorkquist | PFO and PAO | 17,673 | 0.09% | Nov 3, 2026 |
| William E. Delaney IV | Chief Scientific Officer | 74,035 | 0.36% | Nov 3, 2026 |
| Anuj Gaggar | Chief Medical Officer | 53,800 | 0.26% | Nov 3, 2026 |
| Nicole S. White | Chief Manufacturing Officer | 59,257 | 0.29% | Nov 3, 2026 |
| Susan Mahony | Director | – | – | Jun 5, 2026 |
| Lisa Johnson-Pratt | Director | – | – | Jun 5, 2026 |
| Michael Houghton | Director | 3,202 | 0.02% | Jun 5, 2026 |
| Anthony E. Altig | Director | 8,000 | 0.04% | Jun 5, 2026 |
| Gina Consylman | Director | – | – | Jun 5, 2026 |
| John G. McHutchison | Director | 18,347 | 0.09% | Jun 5, 2026 |
| William R. Ringo | Director | 17,465 | 0.09% | Jun 9, 2025 |
| Gilead Sciences, Inc. | 10% owner | 4,977,089 | 24.44% | May 27, 2026 |
| Alexander Schornstein | 10% owner | 1,832,405 | 9.00% | Nov 26, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeanette M. Bjorkquist PFO and PAO | Nov 2, 2026 | Sale | −9 | $20.35 | $183 | 17,673 |
| Jeanette M. Bjorkquist PFO and PAO | Nov 2, 2026 | Sale | −718 | $19.61 | $14.08K | 17,682 |
| Nicole S. White Chief Manufacturing Officer | Nov 2, 2026 | Sale | −29 | $20.35 | $590 | 59,257 |
| Nicole S. White Chief Manufacturing Officer | Nov 2, 2026 | Sale | −2,564 | $19.61 | $50.27K | 59,286 |
| Anuj Gaggar Chief Medical Officer | Nov 2, 2026 | Sale | −29 | $20.35 | $590 | 53,800 |
| Anuj Gaggar Chief Medical Officer | Nov 2, 2026 | Sale | −2,564 | $19.61 | $50.27K | 53,829 |
| Jason A. Okazaki CEO and President, Director | Nov 2, 2026 | Sale | −69 | $20.35 | $1.40K | 195,532 |
| Jason A. Okazaki CEO and President, Director | Nov 2, 2026 | Sale | −6,133 | $19.61 | $120.25K | 195,601 |
| Jeanette M. Bjorkquist PFO and PAO | Oct 30, 2026 | Award | +3,840 | – | – | 18,400 |
| Nicole S. White Chief Manufacturing Officer | Oct 30, 2026 | Award | +13,705 | – | – | 61,850 |
| William E. Delaney IV Chief Scientific Officer | Oct 30, 2026 | Award | +13,705 | – | – | 74,035 |
| Anuj Gaggar Chief Medical Officer | Oct 30, 2026 | Award | +13,705 | – | – | 56,393 |
| Jason A. Okazaki CEO and President, Director | Oct 30, 2026 | Award | +38,380 | – | – | 201,734 |
| Jeanette M. Bjorkquist PFO and PAO | Jun 17, 2026 | Sale | −29 | $23.25 | $674 | 14,560 |
| Gilead Sciences, Inc. 10% owner | May 26, 2026 | Award | +471,698 | $26.50 | $12.50M | 4,977,089 |
| Jeanette M. Bjorkquist PFO and PAO | Mar 30, 2026 | Sale | −312 | $26.65 | $8.31K | 11,105 |
| Jeanette M. Bjorkquist PFO and PAO | Mar 30, 2026 | Sale | −16 | $27.49 | $440 | 11,089 |
| Nicole S. White Chief Manufacturing Officer | Mar 30, 2026 | Sale | −188 | $26.65 | $5.01K | 37,486 |
| Nicole S. White Chief Manufacturing Officer | Mar 30, 2026 | Sale | −9 | $27.49 | $247 | 37,477 |
| William E. Delaney IV Chief Scientific Officer | Mar 29, 2026 | Award | +14,000 | – | – | 60,330 |
| Anuj Gaggar Chief Medical Officer | Mar 29, 2026 | Award | +14,000 | – | – | 42,688 |
| Jeanette M. Bjorkquist PFO and PAO | Mar 29, 2026 | Award | +3,500 | – | – | 14,589 |
| Nicole S. White Chief Manufacturing Officer | Mar 29, 2026 | Award | +14,000 | – | – | 48,145 |
| Jason A. Okazaki CEO and President, Director | Mar 29, 2026 | Award | +50,750 | – | – | 163,354 |
| Jeanette M. Bjorkquist PFO and PAO | Mar 29, 2026 | Award | +6,500 | – | – | 11,417 |
| Nicole S. White Chief Manufacturing Officer | Mar 29, 2026 | Award | +26,000 | – | – | 37,674 |
| William E. Delaney IV Chief Scientific Officer | Mar 29, 2026 | Award | +26,000 | – | – | 45,642 |
| Jason A. Okazaki CEO and President, Director | Mar 29, 2026 | Award | +94,250 | – | – | 111,916 |
| Anuj Gaggar Chief Medical Officer | Mar 29, 2026 | Award | +26,000 | – | – | 28,000 |
| Gilead Sciences, Inc. 10% owner | Aug 8, 2025 | Buy | +2,295,920 | – | – | 4,505,391 |
| Jeanette M. Bjorkquist PFO and PAO | Jun 16, 2025 | Award | +300 | – | – | 5,097 |
| John G. McHutchison Director | Mar 31, 2025 | Sale | −757 | $9.85 | $7.46K | 18,347 |
| Jeanette M. Bjorkquist Principal Accounting Officer | Mar 31, 2025 | Sale | −180 | $9.85 | $1.77K | 4,617 |
| Nicole S. White Chief Manufacturing Officer | Mar 31, 2025 | Sale | −197 | $9.85 | $1.94K | 11,674 |
| Jason A. Okazaki CEO and President, Director | Mar 31, 2025 | Sale | −355 | $9.85 | $3.50K | 14,757 |
| Jeanette M. Bjorkquist Principal Accounting Officer | Mar 29, 2025 | Award | +1,655 | – | – | 4,797 |
| Michael Houghton Director | Dec 30, 2024 | Buy | +3,202 | $15.61 | $49.98K | 3,202 |
| Gilead Sciences, Inc. 10% owner | Dec 19, 2024 | Buy | +940,499 | $21.37 | $20.10M | 2,209,471 |
| Alexander Schornstein 10% owner | Nov 25, 2024 | Buy | +5,000 | $14.85 | $74.25K | 728,113 |
| Alexander Schornstein 10% owner | Nov 25, 2024 | Buy | +2,976 | $15.00 | $44.64K | 723,113 |
| Alexander Schornstein 10% owner | Nov 22, 2024 | Buy | +17,024 | $14.87 | $253.15K | 720,137 |
| Nicole S. White Chief Manufacturing Officer | Nov 18, 2024 | Sale | −40 | $16.29 | $652 | 11,871 |
| Alexander Schornstein 10% owner | Oct 8, 2024 | Buy | +10,000 | $14.58 | $145.80K | 703,113 |
| Nicole S. White Chief Manufacturing Officer | Oct 3, 2024 | Sale | −157 | $14.81 | $2.33K | 11,911 |
| Jason A. Okazaki CEO and President, Director | Oct 3, 2024 | Sale | −197 | $14.81 | $2.92K | 14,904 |
| Jason A. Okazaki CEO and President, Director | Aug 2, 2024 | Sale | −981 | $14.23 | $13.96K | 15,101 |
| Nicole S. White Chief Manufacturing Officer | Aug 2, 2024 | Sale | −785 | $14.23 | $11.17K | 12,068 |
| Alexander Schornstein 10% owner | Jul 5, 2024 | Buy | +4,438 | $12.52 | $55.56K | 693,113 |
| Alexander Schornstein 10% owner | Jul 3, 2024 | Buy | +4,562 | $12.29 | $56.07K | 688,675 |
| Gilead Sciences, Inc. 10% owner | Jun 17, 2024 | Buy | +179,500 | – | – | 1,268,972 |
| John G. McHutchison Director | May 23, 2024 | Sale | −2,117 | $14.93 | $31.61K | 19,104 |
| Jeanette M. Bjorkquist Principal Accounting Officer | May 23, 2024 | Sale | −24 | $14.93 | $358 | 3,142 |
| Jason A. Okazaki CEO and President, Director | May 23, 2024 | Sale | −549 | $14.93 | $8.20K | 16,082 |
| Nicole S. White Chief Manufacturing Officer | May 23, 2024 | Sale | −172 | $14.93 | $2.57K | 12,853 |
| Nicole S. White Chief Manufacturing Officer | Apr 30, 2024 | Sale | −1,255 | $12.71 | $15.95K | 13,025 |
| Jason A. Okazaki CEO and President, Director | Apr 30, 2024 | Sale | −1,569 | $12.71 | $19.94K | 16,423 |
| Nicole S. White Chief Manufacturing Officer | Apr 29, 2024 | Award | +3,333 | – | – | 14,280 |
| Jason A. Okazaki CEO and President, Director | Apr 29, 2024 | Award | +4,166 | – | – | 17,992 |
| William E. Delaney IV Chief Scientific Officer | Apr 29, 2024 | Award | +3,333 | – | – | 16,109 |
| Nicole S. White Chief Manufacturing Officer | Apr 1, 2024 | Sale | −197 | $13.07 | $2.57K | 10,947 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Assembly Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,727 shares on Aug 31, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Nicole S. White Officer | Nov 2, 2026 | 2,593 | $50.86K | Nov 2, 2026 | Restricted Stock Unit Release |
| Anuj Gaggar Officer | Nov 2, 2026 | 2,593 | $50.86K | Nov 2, 2026 | Restricted Stock Unit Release |
| Jason A. Okazaki Officer, Director | Nov 2, 2026 | 6,202 | $121.66K | Nov 2, 2026 | Restricted Stock Unit Release |
| Jason A. Okazaki Officer, Director | Oct 3, 2023 | 2,363 | $2.01K | Oct 3, 2023 | Restricted Stock Unit Release |
| William E. Delaney IV Officer | Oct 3, 2023 | 1,891 | $1.61K | Oct 3, 2023 | Restricted Stock Unit Release |
| Jason A. Okazaki Officer, Director | Aug 2, 2023 | 11,827 | $12.87K | Aug 2, 2023 | Restricted Stock Unit Release |
| William E. Delaney IV Officer | Aug 2, 2023 | 9,461 | $10.29K | Aug 2, 2023 | Restricted Stock Unit Release |
| William E. Delaney IV Officer | May 30, 2023 | 4,232 | $4.05K | May 30, 2023 | Restricted Stock Unit Release |
| John G. McHutchison Director | May 23, 2023 | 25,972 | $27.02K | May 23, 2023 | Restricted Stock Unit Release |
| William E. Delaney IV Officer | May 23, 2023 | 6,561 | $6.83K | May 23, 2023 | Restricted Stock Unit Release |
| Jason A. Okazaki Officer, Director | May 23, 2023 | 6,561 | $6.83K | May 23, 2023 | Restricted Stock Unit Release |
Congress trades
2 trades in Assembly Biosciences reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Sold | Jan 4, 2021 | $1K–15K | Feb 17, 2021 |
| Christopher L. Jacobs NY27 | Bought | Dec 28, 2020 | $1K–15K | Feb 10, 2021 |
See a number that looks wrong?